[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maze Therapeutics Inc (MAZE)

Maze Therapeutics Inc (MAZE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,343,223
  • Shares Outstanding, K 55,345
  • Annual Sales, $ 0 K
  • Annual Income, $ -131,120 K
  • EBIT $ -134 M
  • EBITDA $ -132 M
  • 60-Month Beta 2.26
  • Price/Sales 59.79
  • Price/Cash Flow N/A
  • Price/Book 3.70

Options Overview Details

View History
  • Implied Volatility 95.85% (+18.45%)
  • Historical Volatility 40.62%
  • IV Percentile 58%
  • IV Rank 18.42%
  • IV High 228.70% on 03/10/26
  • IV Low 65.85% on 05/15/26
  • Expected Move (DTE 11) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 112
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 2,034
  • Open Int (30-Day) 2,392
  • Expected Range 24.27 to 24.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.76
  • Number of Estimates 5
  • High Estimate $-0.68
  • Low Estimate $-0.82
  • Prior Year $-0.77
  • Growth Rate Est. (year over year) +1.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.61 +2.77%
on 06/05/26
27.26 -10.97%
on 05/06/26
-2.29 (-8.62%)
since 05/05/26
3-Month
23.61 +2.77%
on 06/05/26
53.65 -54.76%
on 03/16/26
-21.03 (-46.42%)
since 03/05/26
52-Week
9.83 +146.90%
on 06/25/25
53.65 -54.76%
on 03/16/26
+10.93 (+81.93%)
since 06/05/25

Most Recent Stories

More News
Maze Therapeutics to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 24.27 (-4.45%)
Will Maze Therapeutics Finally Explain What Justifies Burning Through That Much Cash?

Barchart Research What to Expect from MAZE Earnings MAZE Generated May 12, 2026 Current Price $25.78 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 10.21% Will Maze Therapeutics Finally...

MAZE : 24.27 (-4.45%)
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026...

MAZE : 24.27 (-4.45%)
Maze Therapeutics Announces $150 Million Registered Offering

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common...

MAZE : 24.27 (-4.45%)
U.S. Jobs Figures Issued in Short Week

MondayFeatured Earnings Maze Therpautics (NASDAQ:MAZE) (Q4) EPS for loss of 73 cents, compared ...

AYI : 302.04 (-1.94%)
MKC : 47.24 (+1.33%)
FDS : 255.62 (+0.24%)
MSM : 115.51 (-1.26%)
CAG : 13.01 (+2.60%)
NKE : 42.98 (-1.47%)
PRGS : 31.36 (-0.60%)
POET : 11.86 (-23.36%)
LW : 42.12 (-0.59%)
ANGO : 11.94 (-0.75%)
MAZE : 24.27 (-4.45%)
LNN : 112.67 (-1.24%)
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated...

MAZE : 24.27 (-4.45%)
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference...

MAZE : 24.27 (-4.45%)
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated...

MAZE : 24.27 (-4.45%)
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference...

MAZE : 24.27 (-4.45%)
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 24.27 (-4.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases. Maze Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif....

See More

Key Turning Points

3rd Resistance Point 27.49
2nd Resistance Point 26.59
1st Resistance Point 25.43
Last Price 24.27
1st Support Level 23.36
2nd Support Level 22.46
3rd Support Level 21.30

See More

52-Week High 53.65
Fibonacci 61.8% 36.91
Fibonacci 50% 31.74
Fibonacci 38.2% 26.57
Last Price 24.27
52-Week Low 9.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.